All Articles

Management of metabolic dysfunction and cardiovascular risk in patients with MASLD

Research and clinical trial design in patients with metabolic dysfunction and alcohol-associated steatotic liver disease (MetALD): a narrative review

Evolving trends and drug class dynamics in drug-induced fatty liver disease over two decades

Fatty liver disease in the pediatric population: history, definitions, and challenges in nomenclature (NAFLD/MAFLD/MASLD)

Shared genetic architecture between metabolic dysfunction-associated steatotic liver disease and cardiometabolic traits comorbidities: a genome-wide pleiotropic and multi-omics study

MASLD or MAFLD: fatty liver by any name will pose the same challenge

NAFLD to MAFLD: collaboration, not confusion - rethinking the naming of fatty liver disease

From NAFLD to MAFLD and MASLD: a tale of alcohol, stigma and metabolic dysfunction

Noninvasive testing in the diagnosis of metabolic dysfunction-associated steatohepatitis

Lower hepatic CBS and PEMT expression in advanced NAFLD: inferencing strategies to lower homocysteine with a mathematical model

Could controversies in the arena of fatty liver disease be a potential gate for the democratization of science?

MASLD, MAFLD, or NAFLD criteria: have we re-created the confusion and acrimony surrounding metabolic syndrome?

Racial and ethnic disparities in metabolic dysfunction-associated steatotic liver disease

Non-metabolic causes of steatotic liver disease

PNPLA3 rs738409 polymorphism and kidney dysfunction: an association beyond nonalcoholic fatty liver disease?

Commentary: Of women, liver, and heart

Ultrasonographic fatty liver indicator (US-FLI): a reliable biomarker for non-invasive NAFLD stratification

The bidirectional relationship between fatty liver disease and COVID-19